A Phase II Study to Determine the Safety and Efficacy of the Dual m-TORC Inhibitor AZD2014 and to Investigate Additional Toxicities in Combination with Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Blood（2017）
Key words
lymphoma,rituximab,dlbcl,inhibitor,m-torc
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined